Turkish biomedical company is looking for partners to apply to Eurostars to further develop a multichannel Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR) device. By diagnosing infectious diseases using the QRT-PCR device, the type of pathogen, and the level of infection are precisely determined. The main objective of the cooperation is to develop a versatile and low-cost multichannel QRT-PCR device. The partnership is a research cooperation agreement to participate in Eurostars.
A Turkish biomedical company founded in 1991 and operated in Ankara, produces medical equipment for hospitals, health institutions, and organizations and establishing full-scale installations. The company aims to provide solutions in order to present a healthy life to humanity under our statement of technologies for life, taking advantage of cutting-edge advancements in line with the international standards in the healthcare sector.
Early diagnosis and prompt treatment are very important to provide the best healthcare to a patient and reduce the risk of further spread, especially in cases such as coronavirus, malaria, tuberculosis. The QRT-PCR test, which is one of the tests applied in the fight against coronavirus, has been heard quite frequently in recent days due to the coronavirus epidemic. By diagnosing infectious diseases using the QRT-PCR device, the type of pathogen, and the level of infection are precisely determined.
QRT-PCR devices are very important not only in the health sector but also in the food and livestock sector. Detection of GMO (Genetically Modified Organisms) content can also be done with QRT-PCR devices. This device is also used in the detection of many animal diseases. There is an intense demand for QRT-PCR devices in the fields of medicine, R&D, forensic sciences, and education. It is aimed to produce the QRT-PCR device that can perform quantitative DNA analyzes of many samples with high precision and quickly. In this device, LEDs emitting at various wavelengths will be used for excitation, and photodiodes, suitable filters, and lenses will be used for emission measurements. Peltier effect materials will be used for heating and cooling processes, and PID technology will be used for temperature control. Polymerase chain reaction (PCR) is a method widely used in molecular biology to rapidly reproduce a very small DNA sample to a sufficiently large quantity. In the polymerase chain reaction (PCR), a specific region between two segments of a known sequence in DNA is enzymatically amplified. Various components and reagents are needed in the PCR method. These are DNA template, DNA polymerase, DNA primers, DNA nucleotide bases (deoxynucleotide triphosphate, dNTP), buffer solution, and buffer ions. Most of the PCR methods rely on thermal cycling. The thermal cycle involves repeated heating and cooling steps, in particular, where the DNA is melted and enzymatically replicating the DNA, allowing temperature-dependent reactions to occur. Based on the principle of reproducing nucleic acids in a reaction tube under suitable conditions, the PCR method consists of denaturation, annealing, and extension/elongation stages. In the denaturation step, the reaction chamber is kept at a temperature between 94 ° C and 98 ° C for 20-30 seconds. In this case, the hydrogen bonds between the complementary bases are broken, the double-stranded DNA template melts, and 2 single-stranded DNA molecules are formed. These, in turn, serve as templates for building the new DNA strand. In the annealing stage, the reaction temperature is lowered between 50 ° C and 65 ° C and waited for 20-40 seconds. Thus, the hydrogen bonding of primers to single-stranded DNA templates is achieved. The annealing temperature should be 3-5 ° C below the melting temperature of the primer used. Primers are single-stranded DNA or RNA sequences of about 20 to 30 bases long. In the PCR method, the amount of DNA is increased by repeating this thermal cycle for a number between 20 and 40.
For their QRT-PCR device, the company is looking for reliable R&D partners such as SMEs experienced in medical device development, including design, product development, validation, product launch, and also for commercialization stages of a Eurostars project proposal on versatile and low-cost multichannel QRT-PCR device. The project duration will be 104 weeks, the deadline for expression of interest is 15/02/2021 and the deadline for the call is 28/02/2021.
- Specific area of activity of the partner: The company is seeking potential partners planning to submit and coordinate a project on Eurostars. A partner with expertise in medical device development including design, product development, validation, and product launch is essential for the project that the company wants to propose.
The innovative aspect of the device to be obtained as a result of the project is that it is cheap and easily accessible, especially for use in the health sector during this pandemic process. With the specially designed optical design, it is expected to make optical reading faster than similar ones. In addition, heating and cooling speeds are thought to be faster than similar ones. In this way, DNA analysis times will be shortened.
Evaluation scheme: The Eurostars program follows a structure that guides you from the conception of your project to after its completion. This is divided into three parts: the application, the evaluation, and the monitoring of successful projects.
Coordinator required: No